Robert Anolik
Allergy & Immunology · Blue Bell, PANPI 1497758536
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $45,575 of the $60,252 with a category attached, or 75.6%. GSK accounts for 83.0% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $26,225 and has fallen 52.2% since, to $12,527 in 2023. Among allergy & immunology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 124 payments — averaging $485.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$50K
- Genentech USA, Inc.$7K
- Regeneron Healthcare Solutions, Inc.$2K
- AstraZeneca$514
- Alk-abello, Inc$179
- Kaleo, Inc.$112
- plus $334 from 9 others
Across 101 payments — averaging $980.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$32K
- AstraZeneca$32K
- Novartis$27K
- Alk-abello, Inc$8K
- Merck$1K
What the payments were for
- Consulting fees$10,30017%
- Speaking & faculty fees$45,57576%
- Travel & lodging$1,7403%
- Food & beverage$2,6374%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 49 | $49,994 |
| Genentech USA, Inc. | 11 | $6,677 |
| Regeneron Healthcare Solutions, Inc. | 3 | $2,442 |
| AstraZeneca | 29 | $514 |
| Alk-abello, Inc | 5 | $179 |
| Kaleo, Inc. | 8 | $112 |
| Sanofi | 5 | $103 |
| Octapharma USA, Inc. | 2 | $46 |
| Boehringer Ingelheim | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Merck | 3 | $32 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $17 |
| CSL Behring | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$60,252 in reported general payments places this provider in the 90th percentile of 175 allergy & immunology providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 12 | $221 |
| Clindamycin Phosphate | 12 | $206 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Blue Bell
- David KrauseBlue Bell$14K
- Mark PosnerBlue Bell$11K
- Patrick VannelliBlue Bell$7K
- Matthew FoggBlue Bell$7K
- Christine MalloyBlue Bell$7K
- Drew WeissmanPhiladelphia$12.8M
- Eric SchenkelBethlehem$845K
- Sergei BelenkyPittsburgh$775K
- Timothy CraigHershey$564K
- Sandra GawchikUpland$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.